FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma

Table 3 The survival analysis of the effect of clinical pathological characteristics on prognosis in ovarian carcinoma

Parameter	Relapse		P value ^a	P value ^b		DOD		P value ^c	P value ^d
Parameter	+	−	P value ^a	P value ^b		+	−	P value ^c	P value ^d
Age
< 57	24	28	0.172		–	17	41	0.240	–
≥ 57	37	26	0.172		–	26	41	0.240	–
FIGO staging system
I–II	9	34	< 0.001		< 0.001	6	37	0.002	0.1
III–IV	52	20	< 0.001		< 0.001	37	45	0.002	0.1
Lymphatic metastasis
No	31	43	0.001		0.595	23	53	0.169	–
Yes	29	10	0.001		0.595	20	27	0.169	–
HDAC3 H-score
Low expreesion	19	40	< 0.001		0.008	9	52	< 0.001	< 0.001
High expression	42	14	< 0.001		0.008	34	30	< 0.001	< 0.001
FOXA1 H-score
Low expression	23	35	0.001		0.853	14	46	0.006	0.951
High expression	38	19	0.001		0.853	29	36	0.006	0.951

DOD death due to disease, cm centimeter, LNM lymph node metastasis
^asingle factor analysis of clinical pathological characteristics and disease-free survival
^bmultifactor analysis of clinical pathological characteristics and disease-free survival
^csingle factor analysis of clinical pathological characteristics and overall survival
^dmultifactor analysis of clinical pathological characteristics and overall survival

ISSN: 1479-5876